Cash-Strapped Annovis Launches Underwritten Offering Days After NYSE Listing Warning
ANVS is trading near its 52-week low of $0.93 (8.5% below the low).
Summary
Annovis launched an underwritten public offering of common stock (or pre-funded warrants) bundled with accompanying warrants; Canaccord Genuity is sole bookrunner and no size or terms were disclosed. The timing is brutal: the stock trades near its 52-week low, the company just disclosed an NYSE notice that its 30-day average market cap fails the continued-listing standard, and it preliminarily reported only about $2.8 million of cash as of September 30. Stockholders approved doubling authorized common stock to 140 million shares the same day, clearing room for exactly this kind of raise. Expect dilution pressure on a micro-cap that already carries a going-concern warning and a warrant liability from prior financings. Pricing terms of the offering are the next hard data point.
At the time of this announcement, ANVS was trading at $0.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.93 to $5.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.